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The cytotoxicity and the antivirus activity of Pd(II) and Pt(II) complexes with pyridine-2-carbaldehyde thiosemicarbazone





on continuous MDBK cells and four HSV 1 and HSV 2 strains were used, two sensitive to acyclovir and two resistant mutants. The
ﬁve complexes of HFoTsc, [Pt(FoTsc)Cl], [Pt(FoTsc)(H2FoTsc)]Cl2,[ P t ( F o T s c ) 2], [Pd(FoTsc)(H2FoTsc)]Cl2, and [Pd(FoTsc)2],
were found to be eﬀective inhibitors of HSV replication. The most promising, active, and selective anti-HSV agent was found to be
complex [Pt(FoTsc)(H2FoTsc)]Cl2. This complex could be useful in the treatment of HSV infections, since it is resistant to ACV
mutants. PCR study of immediate early 300bp ReIV Us1 region reveals that the complex [Pt(FoTsc)(H2FoTsc)]Cl2 speciﬁcally
suppressed wt HSV-1 genome 2 hours after the infection, not inducing apoptosis/necrosis on the 8 hours after virus infection. The
target was found to be most probably the viral, instead of the host cell DNA.
Copyright © 2007 D. Kovala-Demertzi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Herpes simplex viruses (HSVs) are highly adapted human
pathogens with rapid lytic cycle and ability to invade sen-
soryneurons.Theprimary agentsofrecurrentfacialandgen-
ital herpes lesions are HSV-1 and HSV-2 while genital herpes
(GH) is the most common sexually transmitted infection in
the world [1–3]. Moreover, GH is the main factor of increas-
ing three to ﬁve times the risk of HIV transmission, stimu-
lating HIV replication, and ﬁnally leading to the progression
of AIDS [4–6]. Acyclovir (ACV) is a prodrug and it is the
ﬁrst nucleoside-based therapeutic eﬀective for the treatment
D. Kovala-Demertzi, P. Genova, P. Souza, and M. A. Demertzis dedicate this
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of primary and recurrent HSV infections [7]. Eﬀective HSV
suppression with ACV indirectly lowers the HIV load. ACV
has to be phosphorylated by the viral thymidine kinase (TK)
and subsequently by cellular kinases in order to inhibit com-
petitively HSV DNA polymerase and to terminate the viral
DNA chain elongation. However, under systematic admin-
istration, resistant mutants appeared with high frequency
and their main sources are immune-compromised individu-
als[7–9].Thetwomostcommoncausesofresistancearemu-
tationsinthymidinekinase(TK)gene,approximately95%to




maining isolates are usually TK-altered (TK
A) mutants un-
abletophosphorylatetheprodrugbutnotthethymidine[9].
The problem for eﬀective treatment of HSV infections is still




















































Scheme 1: The reaction scheme for the synthesis of the complexes of Pd(II) and Pt(II) with FoTsc {[M(FoTsc)Cl], [M(FoTsc)(H2FoTsc)]Cl2,
[M(FoTsc)2]} [19, 20].
to other nucleoside analogs increase with relatively high fre-
quency.
The earliest antivirals are thiosemicarbazones, Tscs. The
bioactivity of Tscs is due to the inhibition of ribonucleotide
reductase (RR) and due to complexation with essential met-
als [10–12]. The activity of Pt(II) and Pd(II) complexes of
pyridine-2-carbaldehyde (HFoTsc) against the replication of
wild type (wt) HSV-1, was recently referred to by Varadi-
nova et al. [13]. The antiviral activity of platinum complexes
with antiviral agents acyclovir, penciclovir, and famciclovir
has been recently reported [14–16].
T h ea i mo ft h ep r e s e n ts t u d yw a st oe v a l u a t ec o m -
paratively the activity of complexes of Pd(II) and Pt(II)
with pyridine-2-carbaldehyde thiosemicarbazone (HFoTsc)
against HSV replication. Special attention was given to the
eﬃcacy of compounds against ACVR viruses.
2. EXPERIMENTAL
2.1. Metalcomplexes
Solvents were puriﬁed and dried according to standard pro-
cedures. The ligand HFoTsc, 1, and the complexes of Pt(II)
and Pd(II) [PtCl(FoTsc)], 2, [Pt(FoTsc)(H2FoTsc)]Cl2, 3,
[Pt(FoTsc)2],4,[PdCl(FoTsc)],5,[Pd(FoTsc)(H2FoTsc)]Cl2,
6, and [Pd(FoTsc)2], 7, were prepared (see Scheme 1)b y
some of us, as described in the literature [13, 17, 18].
All the compounds were ﬁrstly dissolved in DMSO
(Koch-Light Laboratories Ltd, England) till the concentra-
tion of 1M (stock solutions). Serial tenfold dilutions (100–
0.000001μM) were made from them in cells growth medium
DMEM (Gibco, USA) supplemented with 5% bovine serum
(BS; BioWhittaker, Germany) and antibiotics (penicillin G,
100units/mL, Balkanpharma, Bulgaria).
2.2. Cellsandviruses
Continuous Madin-Darbey bovine kidney (MDBK) cells
were used in the experiments. The cells were grown at 37◦C
in DMEM medium supplemented with 10% BS and an-
tibiotics. During the experimentations, BS content was re-
duced to 5%. Antiviral experiments were done on the fol-
lowing four viruses: two wild (wt) strains Victoria (HSV-1)
and BJA (HSV-2) and two ACVR mutants with diﬀerent TK
gene mutations R-100 (TK
A, HSV-1) and PU (TK
N,H S V - 2 ) .
VirusesweregrowninMDBKcellmonolayers.Cultureswere
harvested at full cytopathic eﬀect (CPE), froze, thawed, and
stored at −70◦C.
2.3. Cytotoxicityand(HSV)assays
Conﬂuent cell monolayers were washed and covered with
media containing the compounds and cultured at 37◦Cf o r
48 hours. Cytopathic eﬀect (CPE) was read by microscopy of
unstained cell monolayers. Cell number was counted by the
Trypan blue-dye exclusion method.
The cytotoxic concentration CC50 (concentration pre-
venting the death of 50% of cells) and the maximal nontoxic
concentration, MNC, were calculated from dose-response
curves. The maximal concentration causing no cytotoxicity
which does not alter the morphology of monolayers and the
cell survival rate was recognized as MNC.
The antiviral activity of the complexes 1–7 against HSV
replication was evaluated on the basis of their eﬀects onD. Kovala-Demertzi et al. 3
the infectious HSV titer. MDBK cells were grown in 96-well
plates and were infected with particular virus in serial ten-
folddilutions.After1hourofvirusattachment,infectedcells
were covered with medium and the tested compound in se-
rial tenfold dilutions (starting from MNC) and cultured at
37◦C for 48 hours (for wt strains) or 72 hours (for ACVR
mutants). Inhibitory concentrations required to inhibit virus
yield by 50% (IC50) were calculated from dose-regression
curves and were indicative for anti-HSV activity. In order to
be able to compare the compounds on the basis of their se-
lective inhibition of virus replication versus cytotoxicity, se-
lective indexes (SI) were calculated as CC50 to IC50 ratio. The




Infected and mocked infected cells cultured in compound-
free medium served as controls. PCR ampliﬁcation 22bp
primers (Applied Biosystems, Calif, USA) were designed ac-
cording to Maertzdorf et al. [21] to amplify 300bp Us1 ReIV
region of HSV-1 genome positions 132333-132634. The se-
quences (5  → 3 ) of the primer were ReIVUs1F-5 TCCG-
ACGACAGAAACCCACC3  and ReIVUs1R-5 GTCCCGG-
AGGACCACAGTGG3 . PCR was performed in a ready-to-
go-PCRbeadsthermocycle(Amersham-PharmaBiotech,NJ,
USA).
A2μl sample of DNA suspension was added to the re-
action mixtures and was overlaid with 25μl of mineral oil
(CinnaGen Inc, Iran). PCR ampliﬁcation was carried out as
follows: an initial denaturation step of 94◦Cf o r5m i n u t e s
followed by 35 cycles of alternating denaturation (94◦Cf o r
30 seconds), primer annealing (60◦C for 60 seconds), and
primer extension (72◦C for 60 seconds). A ﬁnal extension
step of 5 minutes at 72◦C was included. The PCRs were per-
formed in 10μlv o l u m e .B r i e ﬂ y ,2 μlo fe a c hs a m p l ew e r e
added to a separate tube containing 100μlo fl y s i sb u ﬀer
(Applied Biosystems) and stored at −20◦C over night. After
centrifugation at 12000rpm for 5 minutes, the lysis buﬀer
was removed, pellets were resuspended in nucleolysis buﬀer
(300μl) phenol (Sigma Corporation of America, NY, USA),
pH 7.8; 300μl chloroform: isoamyl alcohol = 24 : 1 (Sigma
Corporation of America), and centrifuged at 12000rpm for
5 minutes. DNA was extracted by resuspending the pellets in
10% SDS (Sigma Corporation of America) 10mg/mL pro-
teinase K (Pharma Biotech, USA), 10mM Tris (Sigma Cor-
poration of America ) and 0.1mM EDTA (Sigma Corpora-
tion of America) at pH 7.4 and centrifuged at 12000rpm
for 5 minutes. A volume of 2μl of supernatants containing
50–100ng of the resulting DNA suspension was used per
PCR mixture. The reaction mixture contained 5U/μl cloned
recombinant thermostable STS DNA taq polymerase (Ap-
plied Biosystems), corresponding primers at a concentra-
tionof20μl/mLeach,and5mM/μldeoxynucleosidetriphos-
phate(PharmaBiotech).Ampliconswereelectrophoresedon




The staining methods of one-chain double-helices DNA
have been used with 0.1% solution of acridine orange, and
for mitochondria a solution of 0.1% of Janus green B has
been used. An eukaryotic model of cells infected with HSV
virus was used and the following modiﬁcations in the pur-
pose of adapting the method to the corresponding system
were adapted: (1) ﬁxing of the cell with methanol not with
formaldehyde; (2) after a standard procedure of staining in
view of a further conservation of the preparations, treating
with glycerol PBS = 1 : 1 was used. The experiments were
carried out at the 8 hours of infection in the initial period
of active virus morphogenesis. The following have been used
as controls: (1) cells not infected and untreated with the in-
vestigated compounds; (2) cells not infected but treated with
compounds; (3) cells infected with HSV and cultivated in a
medium without an inhibitor.
The indicators for the lack of apoptosis/necroses were (1)
the apple green ﬂuorescence of cytoplasm and the nuclei ac-
cording to the staining test withacridine orange; (2) a diﬀuse
distribution of mitochondrial, glowing in green according to
the staining test with Janus green B.
The indicators of apoptosis were a glowing of the nuclei
in yellowish-red on a glowing of the cytoplasm in yellowish-
green; a margination of chromatin; and an ejaculation of the
nucleus content.
3. RESULTS AND DISCUSSION
CC50 and MNC values were calculated from dose-
response curves and were presented in Table 1. All the
compounds 1–7 exhibit lower cytotoxicity than ACV. MNC
ranged from 1–100μM. Among them, higher cytotoxic-
ity exhibits [Pt(FoTsc)2] and [Pd(FoTsc)Cl]. These two
complexes are 50 times, [Pd(FoTsc)(H2FoTsc)]Cl2 and
[Pd(FoTsc)2] are 500 times, and HFoTsc, [Pt(FoTsc)Cl] and
[Pt(FoTsc)(H2FoTsc)]Cl2 are 5000 times less cytotoxic than
ACV. The less cytotoxic compounds were HFoTsc (1) and its
Pt(II) complexes 2 and 3. The structure of 3 corresponds to
[M(FoTsc)(H2FoTsc)]X2 [22–24]. Obviously, the protonated
ligand in zwitterion form H2FoTsc+ decreases the cytotoxic-
ity of Pt(II) but not of Pd(II), complex 6.
The data presented on Table 1 show that the cytotoxicity
of compounds 1–7 was predetermined by complex speciﬁci-
ties.
The activity of compounds 1–7 was evaluated against wt
HSV-1, strain Victoria, infection in cultured cells, and the
data were compared to that of ACV. The complex 5 did not
exhibit any eﬀect on the infectious virus yield and it was
excluded from further investigations. The rest of the com-
pounds 1–4, 6–7 were further evaluated against wt HSV-2
strain BJA and two ACVR mutants with diﬀerent TK gene
mutations-R-100 (TK
A)a n dP U( T K
N), see Table 2.
The compounds 1–4 and 6-7 eﬀectively inhibited the
growth of wt a n do fA C V R, HSV-1 and HSV-2 strains and
the eﬀect were found to be predetermined by both complex4 Bioinorganic Chemistry and Applications
Table 1: MNC, CC50,a n dI C 50 (in μM) of HFoTsc and its Pt(II) and Pd(II) metal complexes; NA: not active and ND: not done.
Number Compound CC50 MNC Victoria BJA IC50 R-100 PU
1 HFoTsc 830 100 0.001 0.1 1 1
2 [Pt(FoTsc)Cl] 548 100 0.1 5 0.1 0.1
3 [Pt(FoTsc)(H2FoTsc)]Cl2 5820 100 0.01 0.1 1 1
4 [Pt(FoTsc)2] 40 1 0.006 0.001 0.5 0.5
5 [Pd(FoTsc)Cl] 69 1 NA ND ND ND
6 [Pd(FoTsc)(H2FoTsc)]Cl2 63 10 10 0.01 0.1 0.1
7 [Pd(FoTsc)2]5 9 1 0 0 . 0 6 1 1 1
8 ACV 25 0.02 0.0002 0.002 0.02 0.02
Table 2: Selectivity of HFoTsc and its Pt(II) and Pd(II) complexes
against HSV infection in cultured cells.
Number Compound Selective index (SI)
Victoria BJA R-100 PU
1 HFoTsc 830000 7000 900 700
2 [Pt(FoTsc)Cl] 5480 110 6400 6200
3 [Pt(FoTsc)(H2FoTsc)]Cl2 582000 52000 5300 5200
4 [Pt(FoTsc)2] 6667 20000 7200 40
6 [Pd(FoTsc)(H2FoTsc)]Cl2 6.3 6300 6300 1000
7 [Pd(FoTsc)2] 983 59 590 58
8 ACV 125000 10000 1000 1000
and virus speciﬁcities. The most eﬀective inhibitor of the wt
HSV-1 growth was the ligand 1 while complex 4 was most
sensitive to wt HSV-2. On the contrary, the growth of ACVR
viruses was eﬀectively suppressed by the complexes 2 and 6.
The complexes of Pt(II) and Pd(II) and HFoTsc are arranged
according to their eﬃcacy against all four HSV strains in the
following order:
(i) for wt HSV-1: 1 > 4 > 3 > 2 > 7   6;
(ii) for wt HSV-2: 4 > 6 > 1 = 3   2 > 7;
(iii) for ACVR mutants R-100 and PU: 2 = 6   4 > 3 = 7.
The selectivity of compounds 1–7 is shown in Table 2 and it
was found to be predetermined by both complex and virus
speciﬁcities. Complexes 1–7 are arranged according to their
selectivity in the following order against all four strains:
(i) for wt HSV-1: 1 > 3 ≥ ACV > 4 > 2 ≥ 7   6;
(ii) for wt HSV-2: 3 > 4 > ACV > 1 ≥ 6   2 > 7;
(iii) for ACVR strain R-100: 4 > 2 = 6 > 3 > ACV > 1 > 7;
(iv) for ACVR strain PU: 2 > 3 > 6 = ACV > 1 > 7 = 4.
The complex 3 was more sensitive to wt HSV strains,
while the complex 2 was more sensitive to ACVR mutants.
The complex 7 was the less active and selective inhibitor of
HSV replication and the complex 3 selectively inhibited the
replication of both wt and ACVR viruses.
The signiﬁcant activity and selectivity of 3 are probably
due to the negative inﬂuence on several viral targets. This is
based on the fact that in solution, [M(FoTsc)(H2FoTsc)]X2
complexesdissociatetothemetalcomplex[M(FoTsc)Cl]and




group MM, kd Gene 134HSV-1
control
VP26 γ21 2 U L35 + + + +
VP24 γ 25 U 49 − ++ −
VP22 — 29 UL26 −−++
VP22/22a γ1 39–50 UL48 − ++ +
α-TIF γ15 3 U s4/ + −− +
gG/gD γ15 9 U s6 − + − +
VP11 γ17 1 U L46 − + − +
gE γ19 0 U s8 − ++ +
gH γ2 110–115 UL22 + + + −
gC γ2 130 UL44 + + — +
VP5 γ1 155 UL19 + + + +
Pre- β2/γ1 178–195 UL27 + − + −
gB β2/γ1 240 UL27 + + + +
ouslysuppressingvirus-speciﬁcRRandthesynthesisofDNA
progeny.
Virus-speciﬁc proteins were identiﬁed on the 15 hours
by Western blot analysis. Eleven virus-speciﬁc proteins were
identiﬁed in viral control: VP5, VP22, VP23, α-TIF, TK, gB,
gC, gE, gD, gH, and gG. In the compounds 1, 3,a n d4,
VP23, TK, gG/gD, α-TIF, gH, and gE were not identiﬁed, see
Table 3. These data suggest that compounds 1, 3,a n d4 also
suppress the morphogenesis, cell-to-cell spread, and transac-
tivation of virus genomes.
In view of the fact that HFoTsc and 3 are not only ef-
fective and selective HSV inhibitors, but they also suppress
the expression of the essential structure proteins from the
β(E) and γ(L) kinetic groups, whose synthesis is impossi-
ble without α, IE proteins, the eﬀect of 3 over the expres-
sion of the immediately earliest α, IE genes by means of a di-
rect PCR was studied. A direct multiplication was used with
PCR by a primer, determining region 300bp, corresponding
to ReIV region of Us1. The results of the gel electrophore-
sis of DNA extracted from viral infected control cells and
treated for 2 hours after infection with the HSV-1 with MNC
of [Pt(FoTsc)(H2FoTsc)]Cl2, 3 and HFoTsc and 1 are shownD. Kovala-Demertzi et al. 5
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Figure 1: Ampliﬁcation of ReIV containing region within wt HSV-
1genome.(1)negativecontrol(lane1);(2)markers(lane2);(3)cell
control (mock-infected cells cultured in compound-free medium)
(lane 3); (4) positive control (HSV-1-infected cells cultured in
compound-free medium) (lane 4); (5) [Pt(FoTsc)(H2FoTsc)]Cl2, 3
(lane 5), and (6) HFoTsc, 1 (lane 6).
in Figure 1. Just as expected, it was observed that the DNA
of control MDBK cells appears as a band corresponding to
genomic DNA (Figure 1, lane 3). Incubation of the HSV-1
infected cells with the MNC of [Pt(FoTsc)(H2FoTsc)]Cl2, 3
or the HFoTsc, 1 ligand resulted in a “DNA smears,” which
showsthenonspeciﬁcfragmentationofDNA(Figure 1,lanes
5 and 6, resp.). The results received by direct PCR show that
[Pt(FoTsc)(H2FoTsc)]Cl2, 3 (lane 5), and the ligand HFoTsc
1(lane 6) suppressthe expression of the α, IE virus genes.Al-
together, these data suggest that in MDBK infected cells, the
nonspeciﬁc destruction of viral DNA is obviously caused by
Pt(II) ions [25, 26] and may be due to a speciﬁc induction of
apoptosis.
The eﬀect of 3 o np r o g r a m m e dc e l ld e a t hw a se v a l u a t e d
morphologically in order to study if the observed DNA frag-
mentation is cell- and/or virus-speciﬁc. Using acridine or-
angeandJanusBgreenstainingmorphologicalchangeslead-
ing to irreparable margination of chromatin, an ejaculation
of the nucleus content and other indicators for apoptosis
were not found in wt HSV-1 nor in mock-infected cells on
the 8 hours after the action of [Pt(FoTsc)(H2FoTsc)]Cl2, 3.I t
was observed that complex 3 speciﬁcally aﬀects HSV replica-
tion simultaneously suppressing virus-speciﬁc RR and DNA
polymerase and the expression of virus genome immediately
after entering host cell nucleus. This also explains the non-
speciﬁc virus response to [Pt(FoTsc)(H2FoTsc)]Cl2.
The experimental data show that [Pt(FoTsc)(H2FoTsc)]·
Cl2 complex is a promising anti-HSV agent which could be
useful in the treatment of HSV infections, especially when
the causative agent is resistant to ACV mutants. The plat-
inum complex [Pt(FoTsc)(H2FoTsc)]Cl2 decreases the cyto-
toxicity of Pt(II) ion and directs its activity to viral and not
to host cell DNA.
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